Minute Insight: Xeltis Expects The US Trial Of 'Living' Vascular Graft To Start This Year
Executive Summary
Xeltis hemodialysis access graft, made of its proprietary electrospun supramolecular polymer material, is advancing in clinical trials in Europe and will likely be ready for a US trial by the end of this year, according to the company.